Información del artículo
El Texto completo está disponible en PDF
References
[1.]
Dolor orofacial. Etiologfa, diagnóstico y trata-miento,
[2.]
Principles of analgesic use in the treatment of acute pain and cancer pain, 4a, American Pain Society, (1999),
[3.]
Likar R., Koppert W., Blatnig H., Chiari F., Sittl R., Stein C., et al.
Efficacy of peripheral morphine analgesia in inflamed, non-inflamed and perineural tissue of dental surgery patients.
J Pain Symptom Manage, 21 (2001), pp. 330-337
[4.]
Desjardins PJ., Norris LH., Cooper SA., Reynolds DC..
Analgesic efficacy of intranasal butorphanol (Stadol NS) in the tratment of pain after dental impaction surgery.
J Oral Maxillofac Surg, 58 (2000), pp. 19-26
[5.]
Samad TA., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S, et al.
Interleukin-1b-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.
Nature, 410 (2001), pp. 471-475
[6.]
Ehrich E.W., Dallob A., De Lepeleire I., Van Hecken A., Riendeau D., Yuan W, et al.
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Clin Pharmacol Ther, 65 (1999), pp. 336-347
[7.]
Malmstrom K., Daniels S., Kotey P., Seidenberg B.C., Desjardins P.J..
Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placeboand active-comparator-controlled clinical trial.
Clin Ther, 21 (1999), pp. 1653-1663
[8.]
Morrison BW., Christensen S., Yuan W., Brown J., Amlani S., Seidenberg B..
Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial.
Clin Ther, 21 (1999), pp. 943-953
[9.]
Morrison B.W., Fricke J., Brown J., Yuan W., Kotey P., Mehlisch D..
The optimal analgesic dose of rofecoxib: overview of six randomized controlled trials.
J Am Dental Assoc, 131 (2000), pp. 1729-1737
[10.]
Hawkey C.J., Jackson L., Harper S.E., Simon T.J., Mortensen E., Lines C.R..
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Aliment Pharmacol Ther, 15 (2001), pp. 1-9
[11.]
Rodd H.D., Boissonade F.M..
Substance P expression in human tooth pulp in relation to caries and pain experience.
Eur J Oral Sci, 108 (2000), pp. 467-474
[12.]
Gilbert S.D., Clark T.M., Flores C.M..
Antihyperalgesic activity of epibati-dine in the formalin model of facial pain.
Pain, 89 (2001), pp. 159-165
[13.]
Burnstock G..
Purine-mediated signalling in pain and visceral perception.
Trends Pharmacol Sci, 22 (2001), pp. 182-188
Copyright © 2001. Academia de Ciencias Médicas de Bilbao